Across TCGA pan-cancer cohorts, ZNF384 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF384 data layer compared with 27 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNF384 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF384 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.
CCRCC, LSCC, and PDAC are the cancer types where ZNF384 mass-spec protein most reproducibly stratifies survival.